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Background
Approximately 400 million people worldwide are
infected with chronic hepatitis B (CHB), with
approximately 1 million deaths annually from hepatitis
B virus (HBV)-related cirrhosis and hepatocellular
carcinoma (HCC)1. The majority of Asian patients
acquires HBV either at birth, or within the first few
years after birth, and is characterised by a prolonged
immunotolerant phase followed by a prolonged phase
of immunoclearance. Patients will undergo hepatitis B
e-antigen (HBeAg) seroconversion with development of
antibodies to HBeAg (anti-HBe) during the natural
evolution of the disease, median age of HBeAg
seroconversion being around 35 years. However there
may be ongoing disease progression to cirrhosis and
HCC after HBeAg seroconversion in a proportion of
patients.
Goals of Therapy
The ideal goal of CHB therapy is the complete
eradication of HBV, which is not possible with the
current available treatment. Even loss of the hepatitis B
surface antigen (HBsAg) does not denote complete viral
clearance. Hence, short-term goals include
normalisation of serum alanine aminotransferase (ALT)
levels, HBV DNA suppression, HBeAg seroconversion,
and improvement in liver histology, with the aim of
achieving the long-term goals of preventing liver
cirrhosis, liver failure, and HCC.
Treatment Choices
There are six antiviral agents currently available for the
treatment of CHB: lamivudine, adefovir, entecavir,
telbivudine, interferon (IFN)-?, and pegylated IFN
(peg-IFN). Treatment choice should take into account
several important factors of the agent in question,
namely antiviral efficacy, drug resistance profile, long-
term safety profile, methods of administration, and
cost-effectiveness2.
IFN- and pegylated IFN
Standard IFN- has been shown to be effective in the
treatment of CHB3. However, peg-IFN has largely
surpassed standard IFN in CHB treatment. In one
report using suboptimal dose of standard IFN- , peg-
IFN is superior to standard IFN in HBeAg clearance,
HBV DNA suppression and normalisation of ALT4.
Recent studies have focused on combination or
sequential therapy with lamivudine5. Most studies have
not shown any additional benefit of combining one
year lamivudine treatment to IFN therapy when
assessed at 6 months after stopping of therapies6-11.
Although no additional antiviral efficacy is observed,
there is evidence that the combination of IFN and
lamivudine therapy decreases the development of
lamivudine-resistant mutations9,10. (The limiting of
lamivudine treatment to only one year in these studies
is contrary to most current clinical practice with
nucleoside analogues).
In addition, the long-term effectiveness of standard IFN
has not been consistently shown. Long term benefits
including preventing cirrhosis and HCC were not
observed in earlier studies of Japanese and Chinese
patients12,13. In a more recent retrospective study of
Taiwanese patients with high ALT levels at baseline,
IFN was shown to reduce HCC and cirrhosis in HBeAg-
positive patients compared to untreated controls.
Further results regarding peg-IFN with long off-
treatment follow-up is needed to determine its long-
term efficacy.
Lamivudine
Lamivudine is the first oral antiviral drug approved for
the treatment of CHB, and is effective in reducing the
complications of cirrhosis, including decompensation
and HCC, in both cirrhotic and pre-cirrotic patients. 14,15.
However, lamivudine is associated with high rates of
viral resistance, with a resistance rate of 76% after 8
years of treatment15. The initial benefits conferred by
lamivudine are reduced in patients who develop
lamivudine-resistant mutations during long-term
follow-up16. However, even among those with drug
resistance, the outcome remains better than for
untreated patients14,15. Both adefovir and entecavir are
effective against lamivudine-resistant CHB, and either
can be used.
Adefovir
Adefovir dipivoxil has been shown to be effective in
both HBeAg-positive and HBeAg-negative CHB, as well
as lamivudine-resistant HBV17-19, with proven long-term
efficacy20. However, with newer and more potent
antiviral agents now available, the main role of adefovir
is in patients who have developed resistance to
lamivudine or telbivudine. Some studies have shown
that adefovir monotherapy in lamivudine-resistant
patients is as effective for suppressing HBV DNA as
combination therapy with lamivudine21-23, while other
studies have shown substantially lower rate of
resistance to adefovir when treatment is continued in
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combination with lamivudine24-27. We recommend the
addition of adefovir for lamivudine-resistant patients as
soon as genotypic resistance is detected. Adefovir-
resistant HBV is sensitive to both entecavir and
lamivudine 28.
Entecavir
Entecavir is the third oral antiviral agent approved for
CHB treatment, and is superior to lamivudine29-31.
Furthermore, no virological breakthrough from
entecavir resistance has been observed after 2 years of
treatment in treatment-naive HBeAg-positive patients32.
The resistance rate in treatment-naive patients is only
1.2% in 5 years. Entecavir has been shown to be
effective against lamivudine-resistant HBV at the higher
daily dose of 1 mg instead of the recommended 0.5 mg
daily dose for treatment-naive patients 33,34. However, in
patients with pre-existing lamivudine-resistant
mutations, there is a lower viral response rate, and
higher rate of developing entecavir resistance35. The
reason for the higher rate of resistance is because the
mutations that characterise lamivudine resistance
predispose patients to develop subsequent resistance to
entecavir. Therefore, entecavir switching therapy may
be less optimal than adefovir add-on therapy for CHB
associated with lamivudine resistance.
Telbivudine
Telbivudine has been shown to be more potent than
lamivudine and adefovir against HBV36,37. However,
telbivudine is still associated with higher resistance
rates than adefovir or entecavir38. Resistance to
telbivudine occurs at the same mutation site responsible
for resistance to lamivudine; therefore neither is
essentially effective for one another once resistance
develops. The rate of genotypic resistance after 2 years
of telbivudine treatment is 22% and 8.6% among
HBeAg-positive and HBeAg-negative patients,
respectively 38.
Viral Resistance
The resistance rates of different antiviral agents are
shown in figure 1. Development of drug resistance
remains a major issue as the majority of CHB patients
will require long-term therapy. Flares of hepatitis, liver
decompensation and death have been reported to occur
in patients who develop viral resistance 39.
The development of drug resistance also affects further
treatment options. Patients who developed lamivudine
resistant mutations will have a higher rate of
developing subsequent adefovir resistant mutations
compared to those patients without lamivudine
resistant mutations40. Likewise, as described previously,
patients who have lamivudine-resistant HBV will also
have a higher rate of developing subsequent entecavir
resistance 33.
Given the adverse impact of drug-resistant HBV on the
clinical outcome and on subsequent antiviral therapy,
the risk of developing resistance should be considered
prior to starting antiviral therapy. With the availability
of newer and more potent antiviral drugs, the high
resistance rate associated with lamivudine limits its use
as a first-line agent. However, lamivudine remains the
least expensive oral antiviral agent with the longest and
largest profile of safety data. Use of the roadmap
concept, as outlined later, may identify those patients
who will respond more favourably in the long term.
Treatment Endpoints:
As complete eradication of HBV is currently not
possible with available therapy, various endpoints have
been adopted as surrogate markers of successful
treatment. These include HBeAg seroconversion,
normalisation of ALT, and HBV DNA suppression.
HBeAg seroconversion
Traditionally, HBeAg seroconversion has been used as a
marker of treatment success, and is included in various
treatment guidelines 2,41-43. Those patients who have
undergone HBeAg seroconversion are termed "healthy
carriers", with low HBV DNA levels, normal ALT, and
resolution of necro-inflammatory activity within the
liver 44,45. However, recent studies have shown that over
70% of CHB patients are HBeAg-negative at the time of
developing HCC 46,47.
As disease progression still occurs after HBeAg
seroconversion in patients who acquire the disease at
bir th or during early chi ldhood, HBeAg
seroconversion should therefore be considered as part
of the natural history/progression of CHB infection,
and should be taken as a treatment endpoint only in
conjunction with other criteria, specifically the HBV
DNA and ALT levels 48, 49.
HBV DNA levels
Serum HBV DNA levels have been shown to be
important in both the development of liver cirrhosis
and for development of HCC. Higher levels of HBV
DNA are associated with the development of HCC
independent of the HBeAg status and ALT levels 46, 50.
There is no current level of HBV DNA which is
considered 'safe' from disease progression or from
development of HCC 46. A cut-off level of >2000 IU/mL
was shown to be a strong risk predictor of HCC
independent of HBeAg status, serum ALT and
underlying cirrhosis 50. However, even lower HBV
DNA levels have been associated with the development
of HCC 46. Given the absence of a 'safe' lower limit for
disease non-progression, the optimal treatment goal
should therefore be to suppress HBV DNA to the lowest
possible level, that is, non-detectability by PCR assays.
ALT levels
In Asian CHB patients, it has been shown that patients
with ALT levels below half the upper limit of normal
(ULN) have the lowest risk of complications compared
to those with 0.5 x ULN to 2 x ULN 47.
Patients who have undergone HBeAg seroconversion
with subsequent normal ALT have been traditionally
regarded as "healthy carriers" with no or minimal
disease progression. However, even in patients with
normal ALT after HBeAg seroconversion, the
cumulative probability of developing cirrhosis after 17
years was 13%51. A recent study of CHB patients
showed that 37% of those with persistently normal ALT
had significant fibrosis or inflammation on liver
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histology, and the majority of cases with fibrosis
occurred in those with high-normal ALT 52.
In the light of these recent studies, the cut-off for the
upper limit of normal for ALT is most likely to be
lower than the values that are currently used. Even
patients with ALT in the upper range of the currently
accepted normal range are at risk of developing
cirrhosis. Ongoing disease monitoring with
consideration of antiviral therapy should be given for
patients with significant degree of liver fibrosis.
Furthermore, treating only those patients with ALT >2
x ULN, as indicated by most current guidelines, would
exclude a significant proportion of patients (patients
with ALT 0.5 - 2 x ULN) who would benefit most from
antiviral therapy because of the higher risk of having
or developing significant liver disease in these
patients43.
Candidates for Therapy
In HBeAg-positive patients, the ideal candidates for
treatment would be those with a prolonged phase of
immune-clearance. Immunotolerant patients, that is,
young patients with normal ALT levels, can be
monitored and treatment may not be required until
active hepatitis occurs during the onset of loss of
immunotolerance. Unfortunately, there are as yet no
specific criteria to define or identify the time at which
immunotolerance ends and immune clearance starts.
An elevated ALT level is used as a surrogate marker of
inflammation and histological activity, and as a
marker for loss of immunotolerance. Whether this is
an adequate marker remains to be determined.
Nonetheless, it seems reasonable that patients with
ALT levels between 1 - 2 X ULN should probably be
treated. In patients with evidence of cirrhosis and HBV
DNA >2000 IU/mL, they should receive antiviral
treatment regardless of the ALT levels.
A significant proportion of patients who become
HBeAg-negative with positive anti-HBe will have
elevated HBV DNA levels53. Although the median
HBV DNA levels are lower than for HBeAg-positive
patients, these patients tend to be older and have more
advanced underlying liver disease47. In the current
AASLD guidelines, indications for treatment include
patients with ALT>2 x ULN and HBV DNA levels
>20,000 IU/mL, and no treatment for those with ALT
<1 x ULN irrespective of HBV DNA levels43. This
would exclude a substantial amount of patients who
would be at high risk of disease progression, including
patients who already have cirrhosis. In an alternative
treatment algorithm, indications for treatment
included ALT >1 x ULN and HBV DNA >2,000 IU/mL,
whereas those with HBV DNA <2000 IU/mL and
normal ALT would not be treated2. Both guidelines
suggest liver biopsy to determine disease activity and
stage of fibrosis in patients who have ALT and HBV
DNA levels in the range outside the definite treatment
or within the non-treatment levels 2, 43. The summary
of the AASLD guidelines and the alternative treatment
algorithm is shown in figure 2 and 3 respectively. The
arguments against the current AASLD treatment
guidelines have been summarised in a recent review
article 48.
Duration of Therapy
Given the lack of a clearly defined endpoint in the
treatment of CHB, the duration of therapy is likewise
not clearly defined. The long-term goals of preventing
cirrhosis and the development of HCC are likely to be
achieved by prolonged suppression of HBV replication.
In HBeAg-positive patients, the current AASLD
guidelines suggest stopping treatment 6 months after
HBeAg seroconversion (regardless of HBV DNA or the
ALT levels), and re-treat if relapse should occur 43. An
alternative treatment algorithm suggests that treatment
can be stopped 6-12 months after HBeAg
seroconversion, providing HBV DNA is undetectable
by PCR. The latter approach would seem more
appropriate given the inadequacy of HBeAg
seroconversion alone as a treatment endpoint, and also
the high rate of relapse after discontinuation of therapy.
Close monitoring of patients after stopping therapy is
mandatory. We would recommend checking the HBV
DNA levels 1 month after stopping therapy, and 3
monthly thereafter. Antiviral therapy should be
restarted in those with evidence of reactivation. For
HBeAg-negative patients, both guidelines suggest that
long-term therapy is required.
Long-term antiviral therapy raises the concern about
the development of drug-resistant mutations. Despite
this, patients will still benefit from antiviral therapy
even with the occurrence of drug-resistant mutations. In
patients treated with prolonged lamivudine therapy,
patients with drug-resistant HBV still benefit from
treatment when compared to patients with no
treatment14, 54. With newer and more potent antiviral
drugs with higher genetic barrier, such as entecavir,
resistance is likely to become a lesser problem.
Prolonged antiviral therapy also raises the concern
about drug toxicity. Older agents, such as lamivudine
and adefovir, have established long-term safety data,
whereas newer agents are currently lacking in long-
term data both for efficacy and safety. Despite this,
long-term drug toxicity with long-term therapy is an
unlikely problem given the preclinical safety results of
the currently licensed nucleotide/nucleotide analogues.
In general, all the available oral nucleoside analogs are
well tolerated. The documented nephrotoxic effect of
adefovir occurs rarely at the dose used for HBV
treatment, although renal function should be monitored
regularly whilst patients remain on treatment 55.
The advantage of interferon-based therapy over oral
antiviral therapy is that the duration of therapy is
more clearly defined. However, the optimal length of
interferon therapy remains to be determined. The
advantage of a defined treatment length is offset by its
side effects and the high proportion of patients who
will not respond to IFN therapy and will require
further therapy with oral nucleoside analogs 56. Even
in pat ien ts wi th IFN-assoc ia ted HBeAg
seroconversion, long-term monitoring of HBV DNA
levels should be performed.
Monitoring Therapy
None of the published guidelines provide specific
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criteria for on-treatment monitoring of patients.
During antiviral therapy, the degree of viral
suppression has been shown to be the most important
determinant of therapeutic outcomes57. More
specifically, the importance of effective early viral
suppression in determining long term treatment
outcome has been shown in several studies using
lamivudine , adefovir , peg- IFN-? -2a , and
telbivudine58,59,60,61. A more recent study of lamivudine
treatment has shown that HBV DNA levels of less than
2,000 IU/mL as early as week 4 can be used to predict
accurately HBeAg seroconversion with ALT
normalisation and HBV DNA levels <2000 IU/mL
without emergence of lamivudine-resistant mutations,
at year 5 62.
The use of early monitoring of viral suppression is the
mainstay of the recently published roadmap concept,
as shown in figure 4 63. Assessment at week 12 and 24
for primary non-response and early predictors of
efficacy respectively should be used to guide
subsequent treatment choices63. The roadmap concept
is useful when initiating therapy with a drug with
higher rates of resistance or lower antiviral potency,
and maybe potentially useful in patients with pre-
existing drug-resistant mutations. Recent evidence
showed that early viral suppression with adefovir in
treating lamivudine-resistant HBV was associated
with more favourable outcomes64, 65. Future trials will
determine whether the roadmap concept can be
applied to those patients with pre-existing drug-
resistant mutations.
Conclusions
The treatment paradigm is continuing to evolve with
better understanding of the natural history of HBV
infection. Currently, long-term suppression of HBV
replication should be the primary aim. Although peg-
IFN therapy offers a finite duration of therapy, the
long-term outcomes remain to be fully determined. In
addition, only patients with high ALT levels are
suitable, and a high proportion of patients have a
suboptimal response in terms of HBV DNA
suppression. Although long-term benefits are
established for oral nucleoside/nucleotide analogues,
the benefits of treatment are reduced with the
development of drug-resistant mutations.
The optimal choice of the antiviral agent in treatment-
naive patients should be a drug with high antiviral
potency coupled with a high genetic barrier to reduce
the risk of resistance. Entecavir is a significant
improvement in the current antiviral strategy,
achieving both sustained viral suppression with
minimal risk of drug resistance. If a drug with lower
genetic barrier is used, identifying early factors such as
viral load to predict long-term outcome is important.
This would select out patients most likely to achieve
successful long-term viral suppression with their
current regimens, and an alternative agent can be
offered to those with suboptimal early viral response.
Figure 1. Summary of genotype resistance rates of lamivudine,
adefovir, telbivudine and entecavir in treatment-naive patients from
different studies.
Figure 4. The Roadmap concept in the treatment of chronic hepatitis B
Figure 3. The alternative treatment algorithm for treatment of
hepatitis B
Figure 2. The American Association for the Study of Liver Diseases
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